SomaLogic, Inc. entered an agreement with Amgen that will use SomaLogic’s proteomics technology to help advance Amgen’s drug discovery and development programs. The agreement builds on SomaLogic’s existing collaboration with deCODE genetics, an Amgen subsidiary based in Iceland, and will include broader application across Amgen’s pipeline. SomaLogic’s SomaScan Assay measures the levels of 5,000 proteins in small samples of blood which can be used to identify new biomarkers, novel drug targets...